Future directions in transplantation for aplastic anemia.

Area of Science:

• Hematology
• Transplant Immunology

Background:

• Treatment algorithms for severe aplastic anemia (SAA) are evolving.
• Historically, matched sibling donor hematopoietic cell transplant (HCT) was preferred for younger patients, while immunosuppressive treatment (IST) was for older patients.
• Alternative donor HCT was reserved for relapsed or refractory cases due to toxicity concerns.

Purpose of the Study:

• To review the evolving treatment landscape for severe aplastic anemia.
• To highlight the impact of recent advancements in HCT on donor selection and outcomes.
• To discuss the potential paradigm shift in SAA management.

Main Methods:

• Review of current treatment strategies and recent advancements in hematopoietic cell transplant (HCT) for severe aplastic anemia (SAA).
• Analysis of the impact of reduced-toxicity conditioning regimens and novel graft-versus-host disease prophylaxis.
• Evaluation of outcomes data comparing HCT with alternative donors versus traditional IST.

Main Results:

• Reduced-toxicity conditioning and posttransplant cyclophosphamide have decreased HCT morbidity and mortality.
• Alternative donors are increasingly utilized for SAA.
• Disease-free survival after HCT may now surpass that of IST.
• Ongoing trials are exploring upfront alternative donor HCT, challenging established treatment equipoise.

Conclusions:

• Advancements in HCT, including the use of alternative donors and improved supportive care, are transforming SAA management.
• HCT with alternative donors is becoming a more viable upfront option for SAA patients.
• These changes may lead to a significant shift in the standard of care for SAA.